Hemab Launches With ‘Pipeline In An Asset’ Approach To Rare Blood Disorders
Raises $55m In Series A
Executive Summary
Emerging Company Profile: Backed by investors including Novo Holdings, HealthCap and RA Capital Management, Hemab Therapeutics is bringing together strong technology and deep expertise to ‘leapfrog’ treatment for several rare bleeding and thrombosis disorders into the 21st century.